The Board considered and approved the appointment of Mr. Srinivas Mishra as additional director under the category non executive and Independent Director of the Company
Awaiting price reaction for this filing.
Marksans Pharma's board met on May 19, 2025 and approved audited financial results for Q4 and FY25 with an unmodified opinion from auditors MSKA & Associates. Standalone revenue rose to Rs. 1,174.37 crore (from Rs. 853.27 crore), with profit after tax at Rs. 188.27 crore (vs Rs. 133.76 crore), and EPS of Rs. 4.15. Consolidated revenue grew to Rs. 2,622.85 crore with PAT of Rs. 382.62 crore and EPS of Rs. 8.40. The board recommended a final dividend of Rs. 0.80 per share (80% on face value of Re. 1) for FY25, subject to shareholder approval. Mr. Srinivas Mishra, a former SBI Deputy General Manager with 20+ years in corporate banking, was appointed as an Additional Non-executive Independent Director for 5 years effective April 1, 2025. The board also approved amendments to the Marksans Employees Stock Option Scheme 2024, which has a pool of 23 lakh options available for grant.
Strong FY25 earnings with double-digit revenue and profit growth on both standalone and consolidated basis, alongside a dividend declaration, are positive signals for shareholders. The independent director appointment strengthens board oversight, while the ESOP amendment could dilute equity by up to 23 lakh shares (around 5% of current share capital) once grants are made.